Vanguard Portfolio Management
CCCC icon

Vanguard Portfolio Management’s C4 Therapeutics CCCC Stock Holding History

Vanguard Portfolio Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
+680,094
New +$2.33M ﹤0.01% 2581

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management's CCCC Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 680,094 shares worth $3.18M. The stake represents ﹤0.01% of the portfolio and ranks #2581 among its holdings.

147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Vanguard Portfolio Management held 680,094 shares of C4 Therapeutics worth $3.18M as of Q2 2026.
  • C4 Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2581 holding.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.